

Ex. I

1 UNITED STATES DISTRICT COURT
2 DISTRICT OF NEW JERSEY
3

4 -----x

5 IN RE JOHNSON & JOHNSON) MDL No.
6 TALCUM POWDER PRODUCTS) 16-2738 (FLW)(LHG)
7 MARKETING SALES PRACTICES,)
8 AND PRODUCTS LIABILITY)
9 LITIGATION)
10)
11 THIS DOCUMENT RELATES TO)
12 ALL CASES)

13 -----x

14

15 V O L U M E I I I

16 VIDEOTAPED 30(b)(6) DEPOSITION OF DEFENDANT
PERSONAL CARE PRODUCTS COUNCIL

17 by and through its Designated Representative,

18 LINDA LORETZ, Ph.D.

19 WASHINGTON, D.C.

20 TUESDAY, OCTOBER 2, 2018

21 9:01 A.M.

22

23

24

25 Reported by: Leslie A. Todd

1 Q Mm-hmm. Now, the decision that is made
2 by an CI -- a CIR expert panel, what weight does
3 that have with the FDA?

4 MR. LOCKE: Objection to form and beyond
5 the scope.

6 THE WITNESS: I think FDA has
7 consistently said that they take into account CIR
8 conclusions. It's one piece of evidence.

9 BY MR. MEADOWS:

10 Q Okay. But they don't -- the FDA does
11 not adopt a CIR finding, does it?

12 A That's true.

13 Q In fact, the FDA has specifically said
14 that, correct?

15 A They have.

16 Q Okay. I want to look at Exhibit 91.
17 (Exhibit No. 91 was marked for
18 identification.)

19 BY MR. MEADOWS:

20 Q And this Exhibit 91 is from
21 PCPC-MDL-44971.

22 Do you recognize that document?

23 A I don't think so.

24 Q Okay. It does appear to come from the
25 PCPC files; is that right?